Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)

NCT04755283 is registered in ClinicalTrials.gov with Anthos Therapeutics, Inc. as lead sponsor.

NCT NCT04755283
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04755283 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
Lead sponsor
Anthos Therapeutics, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 2, 2021
Completion date
December 29, 2028
Enrollment
1,287 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af), stroke